Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: global cancer statistics 2018. CA Cancer J Clin [Internet]. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Stat. 2020;70:7–30.
   Web of Science ®Google Scholar
• Types of Cancer Treatment. [Internet]. Natl Cancer Inst. 2021. https://www.cancer.gov/about-cancer/treatment/types
   Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–290.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086.
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507–519.
   PubMed Web of Science ®Google Scholar
• Alteber Z, Kotturi MF, Whelan S, et al. Therapeutic targeting of checkpoint receptors within the DNAM1 axis. Cancer Discov. 2021;11:1040–1051.
   PubMed Web of Science ®Google Scholar
• Quagliariello V, Passariello M, Rea D, et al. Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models. J Pers Med [Internet]. 2020;10:179.
   Web of Science ®Google Scholar
• Quagliariello V, Passariello M, Coppola C, et al. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. Int J Cardiol [Internet]. 2019;292:171–179.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol [Internet]. 2022;19:254–267.
   PubMed Web of Science ®Google Scholar
• Bernhardt G. TACTILE becomes tangible: CD96 discloses its inhibitory peculiarities. Nat Immunol. 2014;15:406–408.
   PubMed Web of Science ®Google Scholar
• Minton K. A TACTILE restraint. Nat Rev Immunol. 2014;14:285.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Watson GM, Fu Z, et al., Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155. Structure. 2019;27(219–228.e3):219–228.e3.
   PubMedGoogle Scholar
• Dougall WC, Kurtulus S, Smyth MJ, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112–120.
   PubMed Web of Science ®Google Scholar
• Chan CJ, Martinet L, Gilfillan S, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:431–438.
   PubMed Web of Science ®Google Scholar
• Wang PL, O’Farrell S, Clayberger C, et al. Identification and molecular cloning of tactile: a novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol. 1992;148:2600–2608.
   PubMed Web of Science ®Google Scholar
• Stanko K, Iwert C, Appelt C, et al. CD96 expression determines the inflammatory potential of IL-9-producing Th9 cells. PNAS. 2018;115:2940–2949.
   Web of Science ®Google Scholar
• Toutirais O, Cabillic F, Le Friec G, et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells. Eur J Immunol. 2009;39:1361–1368.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Cella M, Giurisato E, et al. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol. 2004;172:3994–3998.
   PubMed Web of Science ®Google Scholar
• Lepletier A, Lutzky VP, Mittal D, et al. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. Immunol Cell Biol. 2019;97:152–164.
   PubMed Web of Science ®Google Scholar
• Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. PNAS. 2007;104:11008–11013.
   PubMed Web of Science ®Google Scholar
• Chávez-González A, Dorantes-Acosta E, Moreno-Lorenzana D, et al. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Arch Med Res. 2014;45:343–350.
   PubMed Web of Science ®Google Scholar
• Gramatzki M, Ludwig WD, Burger R, et al. Antibodies TC-12 (“unique”) and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol. 1998;26:1209–1214.
   PubMed Web of Science ®Google Scholar
• Zhang W, Shao Z, Fu R, et al. Expressions of CD96 and CD123 in bone marrow cells of patients with myelodysplastic syndromes. Clin Lab. 2015;61:1429–1434.
   PubMed Web of Science ®Google Scholar
• Meyer D, Seth S, Albrecht J, et al. CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. J Biol Chem. 2009;284:2235–2244.
   PubMed Web of Science ®Google Scholar
• Schneider H, Rudd CE. Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4. Front Immunol. 2014;5:619.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, C Gonzalez L, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2008;10:48–57.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Rovis TL, Glasner A, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013;43:2138–2150.
   PubMed Web of Science ®Google Scholar
• Meng F, Li L, Lu F, et al. Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes. Front Oncol. 2020;10:1595.
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Kim HJ, Wu H, et al. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti–PD-1 response in follicular lymphoma. Clin Cancer Res. 2020;26:5217–5231.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow S-F, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–4062.
   PubMed Web of Science ®Google Scholar
• Jin Z, Lan T, Zhao Y, et al. Higher TIGIT(+)CD226(-) γδ T cells in patients with acute myeloid leukemia. Immunol Invest. 2020;51:1–11.
   Web of Science ®Google Scholar
• Reches A, Ophir Y, Stein N, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8:e000266.
   PubMed Web of Science ®Google Scholar
• Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8:e000957.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Li M, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20:456–464.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci. 2009;106:17858L–17863 .
   PubMed Web of Science ®Google Scholar
• Li M, Xia P, Du Y, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem. 2014;289:17647–17657.
   PubMed Web of Science ®Google Scholar
• Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573–581.
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557–567.
   PubMed Web of Science ®Google Scholar
• Pende D, Bottino C, Castriconi R, et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol. 2005;42:463–469.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Paniccia A, Schulick AC, et al. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016;213:167–176.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu N, Lu Y, et al. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212:2165–2182.
   PubMed Web of Science ®Google Scholar
• Ralston KJ, Hird SL, Zhang X, et al. The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large. J Biol Chem. 2004;279:33816–33828.
   PubMed Web of Science ®Google Scholar
• Enqvist M, Ask EH, Forslund E, et al. Coordinated expression of DNAM-1 and LFA-1 in educated NK cells. J Immunol. 2015;194:4518–4527.
   PubMed Web of Science ®Google Scholar
• Shibuya A, Lanier LL, Phillips JH. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol. 1998;161:1671–1676.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Shirakawa J, Kameyama T, et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 2003;198:1829–1839.
   PubMed Web of Science ®Google Scholar
• Kim HS, Das A, Gross CC, et al. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity. 2010;32:175–186.
   PubMed Web of Science ®Google Scholar
• Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal. 2012;5:ra49.
   PubMed Web of Science ®Google Scholar
• Wu B, Zhong C, Lang Q, et al. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res. 2021;40:267.
   PubMed Web of Science ®Google Scholar
• Wang N, Yi H, Fang L, et al. CD226 attenuates treg proliferation via Akt and Erk Signaling in an EAE Model. Front Immunol. 2020:11. DOI:10.3389/fimmu.2020.00011.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Chauvin J-M, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018;3(14):e121157.
   Web of Science ®Google Scholar
• Takai Y, Irie K, Shimizu K, et al. Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci. 2003;94:655–667.
   PubMed Web of Science ®Google Scholar
• He Y, Bowman VD, Mueller S, et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci. 2000;97:79L–84 .
   PubMed Web of Science ®Google Scholar
• Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855–865.
   PubMed Web of Science ®Google Scholar
• Sloan KE, Eustace BK, Stewart JK, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4:73.
   PubMed Web of Science ®Google Scholar
• Gao J, Zheng Q, Xin N, et al. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108:1934–1938.
   PubMed Web of Science ®Google Scholar
• Tahara-Hanaoka S, Shibuya K, Onoda Y, et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol. 2004;16:533–538.
   PubMed Web of Science ®Google Scholar
• Holmes VM, Maluquer de Motes C, Richards PT, et al. Interaction between nectin-1 and the human natural killer cell receptor CD96. PLoS One. 2019;14:e0212443.
   PubMed Web of Science ®Google Scholar
• Geraghty RJ, Krummenacher C, Cohen GH, et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science. 1998;280:1618–1620.
   PubMed Web of Science ®Google Scholar
• Seth S, Maier MK, Qiu Q, et al. The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Commun. 2007;364:959–965.
   PubMed Web of Science ®Google Scholar
• Lopez M, Aoubala M, Jordier F, et al. The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood. 1998;92:4602–4611.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Gayoso I, Bergua JM, et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012;90:109–115.
   PubMed Web of Science ®Google Scholar
• Casado JG, Pawelec G, Morgado S, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009;58:1517–1526.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny YM, Meade JL, Holmes TD, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67:8444L–8449 .
   PubMed Web of Science ®Google Scholar
• Miao X, Yang Z-L, Xiong L, et al. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int J Clin Exp Pathol. 2013;6:179–190.
   PubMed Web of Science ®Google Scholar
• Satoh-Horikawa K, Nakanishi H, Takahashi K, et al. Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities. J Biol Chem. 2000;275:10291–10299.
   PubMed Web of Science ®Google Scholar
• Devilard E, Xerri L, Dubreuil P, et al. Nectin-3 (CD113) interacts with Nectin-2 (CD112) to promote lymphocyte transendothelial migration. PLoS One. 2013;8:e77424–e77424.
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Sho M, Yasuda S, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30.
   PubMed Web of Science ®Google Scholar
• Manes TD, Pober JS. Identification of endothelial cell junctional proteins and lymphocyte receptors involved in transendothelial migration of human effector memory CD4+ T cells. J Immunol. 2011;186:1763–1768.
   PubMed Web of Science ®Google Scholar
• Eriksson EM, Keh CE, Deeks SG, et al. Differential expression of CD96 surface molecule represents CD8+ T cells with dissimilar effector function during HIV-1 infection. PLoS One. 2012;7:e51696–e51696.
   PubMedGoogle Scholar
• Sun H, Huang Q, Huang M, et al. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma. Hepatology. 2019;70:168–183.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Björkström NK, Norell H, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317–1325.
   PubMed Web of Science ®Google Scholar
• Whelan S, Ophir E, Kotturi MF, et al. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8(+) T-cell Function. Cancer Immunol Res. 2019;7:257–268.
   PubMed Web of Science ®Google Scholar
• Chiang EY, de Almeida PE, de Almeida Nagata DE, et al. CD96 functions as a co-stimulatory receptor to enhance CD8 + T cell activation and effector responses. Eur J Immunol. 2020;50:891–902.
   PubMed Web of Science ®Google Scholar
• Feng M, Wu Z, Zhou Y, et al. BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer. Signal Transduct Target Ther. 2021;6:313.
   PubMed Web of Science ®Google Scholar
• Mittal D, Lepletier A, Madore J, et al. CD96 Is an Immune Checkpoint That Regulates CD8(+) T-cell Antitumor Function. Cancer Immunol Res. 2019;7:559–571.
   PubMed Web of Science ®Google Scholar
• Bi J, Zhang Q, Liang D, et al. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis. Hepatology. 2014;59:1715–1725.
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569–581.
   PubMed Web of Science ®Google Scholar
• Weulersse M, Asrir A, Pichler AC, et al. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity [Internet]. 2020;53:824–839.e10.
   PubMed Web of Science ®Google Scholar
• Braun M, Aguilera AR, Sundarrajan A, et al. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. Immunity. 2020;53:805–823.e15.
   PubMed Web of Science ®Google Scholar
• Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov. 2003;2:611–612.
   PubMed Web of Science ®Google Scholar
• Yang F, Zhao L, Wei Z, et al. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. J Immunol. 2020;205:ji1901413.
   Web of Science ®Google Scholar
• Lupo KB, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol. 2020;13:76.
   PubMed Web of Science ®Google Scholar
• Nishiwada S, SHO M, Yasuda S, et al. Clinical Significance of CD155 Expression in Human Pancreatic Cancer. Anticancer Res. 2015;35:2287L–2297 .
   PubMed Web of Science ®Google Scholar
• Gong J, Fang L, Liu R, et al. UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells. Eur J Immunol. 2014;44:3758–3767.
   PubMed Web of Science ®Google Scholar
• Lepletier A, Madore J, O’Donnell JS, et al. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clin Cancer Res. 2020;26:3671–3681.
   PubMed Web of Science ®Google Scholar
• Sun Y, Luo J, Chen Y, et al. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). Int Immunopharmacol. 2020;80:106198.
   PubMed Web of Science ®Google Scholar
• He W, Zhang H, Han F, et al. CD155T/TIGIT Signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77:6375–6388.
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Ishida M, Yanai H, et al. Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. PLoS One. 2021;16:e0253176.
   PubMedGoogle Scholar
• Masson D, Jarry A, Baury B, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49:236–240.
   PubMed Web of Science ®Google Scholar
• Papanicolau-Sengos A, Yang Y, Pabla S, et al. Identification of targets for prostate cancer immunotherapy. Prostate. 2019;79:498–505.
   PubMed Web of Science ®Google Scholar
• Smazynski J, Hamilton PT, Thornton S, et al. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecol Oncol. 2020;158:167–177.
   PubMed Web of Science ®Google Scholar
• Wu L, Mao L, Liu J-F, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res. 2019;7:1700–1713.
   PubMed Web of Science ®Google Scholar
• Mao L, Xiao Y, Yang Q-C, et al. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. Oral Oncol. 2021;121:105472.
   PubMed Web of Science ®Google Scholar
• Liu F, Huang J, He F, et al. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Sci Rep. 2020;10:10768.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhong H, Fan Y, et al. Immune and clinical features of CD96 expression in glioma by in silico analysis. Front Bioeng Biotechnol. 2020;8:592.
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7:e1466769.
   PubMed Web of Science ®Google Scholar
• Iguchi-Manaka A, Okumura G, Kojima H, et al. Increased Soluble CD155 in the Serum of Cancer Patients. PLoS One. 2016;11:e0152982–e0152982.
   PubMedGoogle Scholar
• Sloan KE, Stewart JK, Treloar AF, et al. CD155/PVR Enhances Glioma Cell Dispersal by Regulating Adhesion Signaling and Focal Adhesion Dynamics. Cancer Res. 2005;65:10930L–10937 .
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525–543.
   PubMed Web of Science ®Google Scholar
• Chiu DK-C, Yuen VW-H, Cheu JW-S, et al. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology. 2020;159:609–623.
   PubMed Web of Science ®Google Scholar
• Ge Z, Zhou G, Campos Carrascosa L, et al. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2021;12:443–464.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Sánchez-Paulete AR, Cueto FJ, Martínez-López M, et al. Cancer Immunotherapy with immunomodulatory anti-CD137 and Anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016;6:71L–79 .
   PubMed Web of Science ®Google Scholar
• Rethacker L, Roelens M, Bejar C, et al. Specific patterns of blood ILCs in metastatic melanoma patients and their modulations in response to immunotherapy. Cancers (Basel). 2021;14:13.
   PubMedGoogle Scholar
• Chauvin J-M, Ka M, Pagliano O, et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin Cancer Res. 2020;26:5520–5533.
   PubMed Web of Science ®Google Scholar
• Ma L, Gai J, Qiao P, et al. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. Biochem Biophys Res Commun. 2020;531:144–151.
   PubMed Web of Science ®Google Scholar
• Inozume T, Yaguchi T, Furuta J, et al. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol. 2016;136:255–263.
   PubMed Web of Science ®Google Scholar
• Blake SJ, Stannard K, Liu J, et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 2016;6:446–459.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Q, Lei Y, et al. Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma. Cell Mol Immunol. 2020;18:1575–1577.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38:9503.
   Web of Science ®Google Scholar
• Peng Y-P, Xi C-H, Zhu Y, et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget. 2016;7:66586–66594.
   PubMedGoogle Scholar
• Freed-Pastor WA, Lambert LJ, Ely ZA, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021;39(1342–1360.e14). DOI:10.1016/j.ccell.2021.07.007.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
   PubMed Web of Science ®Google Scholar
• Stamm H, Oliveira-Ferrer L, Grossjohann E-M, et al. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology. 2019;8:e1674605.
   PubMed Web of Science ®Google Scholar
• Chen C, Guo Q, Fu H, et al. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials. 2021;275:120988.
   PubMed Web of Science ®Google Scholar
• Maas RJ, Hoogstad-van Evert JS, Van der Meer JM, et al. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology. 2020;9:1843247.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6:92.
   PubMed Web of Science ®Google Scholar
• Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015;263:90–105.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Prim [Internet]. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood. 2018;132:1689–1694.
   PubMed Web of Science ®Google Scholar
• Mohammad H, Wahba Y, Gouida M, et al. Cluster of differentiation 96 in children with acute leukemia: a single center cohort study. Indian J Hematol Blood Transfus. 2020;36:178–182.
   PubMed Web of Science ®Google Scholar
• Valhondo I, Hassouneh F, Lopez-Sejas N, et al. Characterization of the DNAM-1, TIGIT and TACTILE axis on circulating NK, NKT-like and T cell subsets in patients with acute myeloid leukemia. Cancers (Basel). 2020;12(8):2171.
   Google Scholar
• Xu L, Liu L, Yao D, et al. PD-1 and TIGIT are highly co-expressed on CD8(+) T cells in AML Patient bone marrow. Front Oncol. 2021;11:686156.
   PubMed Web of Science ®Google Scholar
• Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR–dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113:3503–3511.
   PubMed Web of Science ®Google Scholar
• Ye W, Luo C, Liu F, et al. CD96 correlates with immune infiltration and impacts patient prognosis: a pan-cancer analysis. Front Oncol. 2021;11:634617.
   PubMedGoogle Scholar
• Song X, Tang T, Li C, et al. CBX8 and CD96 are important prognostic biomarkers of colorectal cancer. Med Sci Monit. 2018;24:7820–7827.
   PubMed Web of Science ®Google Scholar
• So YK, Byeon S-J, Ku BM, et al. An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC. Sci Rep. 2020;10:20059.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fu M, Zhang M, et al. DDX60 is associated with glioma malignancy and serves as a potential immunotherapy biomarker. Front Oncol. 2021;11:665360.
   PubMed Web of Science ®Google Scholar
• Miyashita M, Oshiumi H, Matsumoto M, et al. DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol. 2011;31:3802–3819.
   PubMed Web of Science ®Google Scholar
• Lozano E, Mena M-P, Díaz T, et al. Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple Myeloma. Clin Cancer Res. 2020;26:4688–4698.
   PubMed Web of Science ®Google Scholar
• Jin H-S, Ko M, Choi D-S, et al. CD226(hi)CD8(+) T cells are a prerequisite for anti-TIGIT immunotherapy. Cancer Immunol Res. 2020;8:912–925.
   PubMed Web of Science ®Google Scholar
• Drake CG. Combination immunotherapy approaches. Ann Oncol. 2012;23:41–46.
   Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–584.
   PubMed Web of Science ®Google Scholar
• Raphael I, Kumar R, McCarl LH, et al. TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma. Front Immunol. 2021;12:637146.
   PubMed Web of Science ®Google Scholar
• Hansen K, Kumar S, Logronio K, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021;70:3525–3540.
   PubMed Web of Science ®Google Scholar
• Grapin M, Richard C, Limagne E, et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019;7:160.
   PubMed Web of Science ®Google Scholar
• Li X-Y, Das I, Lepletier A, et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018;128:2613–2625.
   PubMed Web of Science ®Google Scholar
• Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125:2046–2058.
   PubMed Web of Science ®Google Scholar
• Han HS, Jeong S, Kim H, et al. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 2021;499:137–147.
   PubMed Web of Science ®Google Scholar
• Xu F, Sunderland A, Zhou Y, et al. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017;66:1367–1375.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–937.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhao Q, Zhang Y, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40:24.
   PubMed Web of Science ®Google Scholar
• Fathi M, Bahmanpour S, Barshidi A, et al. Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. Int Immunopharmacol. 2021;101:108288.
   PubMed Web of Science ®Google Scholar
• Mo Z, Liu D, Rong D, et al. Hypoxic characteristic in the immunosuppressive microenvironment of hepatocellular carcinoma. Front Immunol. 2021;12:611058.
   PubMed Web of Science ®Google Scholar
• Klümper N, Ralser DJ, Bawden EG, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020;8:e000552.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–1288.
   PubMed Web of Science ®Google Scholar
• Woods DM, Sodré AL, Villagra A, et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3:1375–1385.
   PubMed Web of Science ®Google Scholar
• Li X, Su X, Liu R, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40:1836–1850.
   PubMed Web of Science ®Google Scholar
• Llopiz D, Ruiz M, Villanueva L, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother. 2019;68:379–393.
   PubMed Web of Science ®Google Scholar
• Chen X, Pan X, Zhang W, et al. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10:723–733.
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Lee HJ, Kim HC, et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022;30:579–592.
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471–482.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CPM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–5646.
   PubMed Web of Science ®Google Scholar
• Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24:1135–1149.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130–3144.
   PubMed Web of Science ®Google Scholar
• Jackson Z, Hong C, Schauner R, et al. Sequential single cell transcriptional and protein marker profiling reveals tigit as a marker of CD19 CAR-T cell dysfunction in patients with non-hodgkin’s lymphoma. Blood. 2021;138:164.
   Web of Science ®Google Scholar
• Ma H, Wang H, Sové RJ, et al. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. J Immunother Cancer. 2020;8:e001141.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Q, Zeng X, et al. MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING. Cancer Discov. 2021;11:2726–2737. candisc.1500.2020.
   PubMed Web of Science ®Google Scholar
• Zhou X, Du J, Wang H, et al. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell Commun Signal. 2020;18:142.
   PubMed Web of Science ®Google Scholar
• Zhou X, Jiao L, Qian Y, et al. Repositioning azelnidipine as a dual inhibitor targeting CD47/SIRPα and TIGIT/PVR pathways for cancer immuno-therapy. Biomolecules. 2021;12:11.
   PubMedGoogle Scholar
• Harjunpää H, Blake SJ, Ahern E, et al. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncoimmunology [Internet]. 2018;7:e1445949.
   PubMed Web of Science ®Google Scholar
• Waliany S, Lee D, Witteles RM, et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol [Internet]. 2021;61:113–134.
   PubMed Web of Science ®Google Scholar